Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Panelists say AAV manufacturing, funding cuts and workforce are central barriers to scaling gene therapies
Summary
Industry leaders at a Columbus Metropolitan Club forum discussed technical challenges in producing AAV gene therapies at scale, steps companies are taking to increase yield, and concern about federal research funding declines affecting the innovation pipeline.
Executives and investors on a Columbus Metropolitan Club panel described both scientific progress and practical obstacles to scaling gene‑therapy production and bringing treatments to patients.
“Scaling up adeno associated viruses is quite challenging,” said Frank Obobo, vice president of process development at Forge Biologics, describing process development and the company’s move to GMP manufacturing for AAV vectors. He added that Forge has grown its workforce and served more than 50 clients while expanding capacity.
Obobo said the company has worked on process…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
